{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:05:30Z","timestamp":1790892330428,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To conduct post hoc analyses of the VERTIS CV (NCT01986881) trial to explore the effects of ertugliflozin on serum uric acid (UA) and gout\u2010related outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Participants with type 2 diabetes and atherosclerotic cardiovascular disease were randomised (1:1:1) to placebo, ertugliflozin 5\u2009mg or ertugliflozin 15\u2009mg. Mean UA over time (260\u2009weeks) was evaluated for pooled ertugliflozin versus placebo overall, and by baseline quintile of UA (\u22644.3\u2009mg\/dL [\u2264255.8 \u00b5mol\/L], &gt;4.3\u20135.1\u2009mg\/dL [&gt;255.8\u2013303.4 \u00b5mol\/L], &gt;5.1\u20135.8\u2009mg\/dL [&gt;303.4\u2013345.0 \u00b5mol\/L], &gt;5.8\u20136.9\u2009mg\/dL [&gt;345.0\u2013410.4 \u00b5mol\/L] and\u2009&gt;6.9\u2009mg\/dL [&gt;410.4 \u00b5mol\/L]), glycated haemoglobin level, albuminuria status, estimated glomerular filtration rate and KDIGO (Kidney Disease: Improving Global Outcomes in Chronic Kidney Disease) risk category. The effect of ertugliflozin on a composite of gout onset or initiation of anti\u2010gout medication was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean UA levels at baseline were 5.67 and 5.62\u2009mg\/dL in the placebo and ertugliflozin groups, respectively. Ertugliflozin reduced UA over Weeks 6\u2013260 compared with placebo, with least squares mean (LSM) changes (95% confidence interval [CI]) from baseline at Week 260 of 0.07\u2009mg\/dL (\u22120.02, 0.15) and \u22120.19\u2009mg\/dL (\u22120.25, \u22120.13) in the placebo and pooled ertugliflozin groups, respectively. At Week 260, placebo\u2010adjusted LSM change (95% CI) from baseline in UA was \u22120.26\u2009mg\/dL (\u22120.36, \u22120.16) with ertugliflozin. Ertugliflozin was associated with reductions in UA across baseline UA quintiles compared with placebo. The incidence of the composite of gout\u2010related outcomes was 84\/2539 (3.3%) for placebo and 133\/5091 (2.6%) for ertugliflozin (hazard ratio for the composite 0.76 [95% CI 0.580, 1.002]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ertugliflozin was generally associated with lowering UA overall and across subgroups compared with placebo, and numerically reduced rates of gout\u2010related outcome events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15895","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T03:44:35Z","timestamp":1725248675000},"page":"5336-5346","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of ertugliflozin on uric acid and gout\u2010related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from\n                    <scp>VERTIS CV<\/scp>"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7947-1822","authenticated-orcid":false,"given":"Vikas S.","family":"Sridhar","sequence":"first","affiliation":[{"name":"Toronto General Hospital Research Institute University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[{"name":"Unit of Cardiology Karolinska Institute &amp; Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Dagogo\u2010Jack","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine UT Southwestern Medical Center  Dallas Texas USA"},{"name":"Parkland Health  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Pratley","sequence":"additional","affiliation":[{"name":"AdventHealth Translational Research Institute  Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilo B.","family":"Cater","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Noyes Essex","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Mancuso","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z. I.","family":"Cherney","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes211"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179221"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes223"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.01.019"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","unstructured":"EssexMN HoppsM UdallM et al.Relationship of serum uric acid levels with cardiovascular disease in patients with gout: a retrospective analysis of electronic health record data. The European League Against Rheumatism Congress Rome Italy 2015.","DOI":"10.1136\/annrheumdis-2015-eular.3567"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","unstructured":"EssexMN HoppsM UdallM et al.Does high serum uric acid increase the risk of renal disease in patients with gout? Results from a retrospective analysis of electronic health record data. The European League Against Rheumatism Congress Rome Italy 2015 FRI0324.","DOI":"10.1136\/annrheumdis-2015-eular.3602"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000496"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1427-5"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0610-9"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.582680"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2017.04.008"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001358"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021372"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/gucdd2010008"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.5608"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30078-5"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14559"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.04.051"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.08.004"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20233411S1854c"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/db22-859-P"},{"key":"e_1_2_10_27_1","first-page":"318","article-title":"621: effects of ertugliflozin on uric acid and gout\u2010related outcomes: post hoc analyses from VERTIS CV","volume":"65","author":"Sridhar VS","year":"2022","journal-title":"Diabetologia"},{"key":"e_1_2_10_28_1","first-page":"832","article-title":"256. Effects of ertugliflozin on uric acid and gout\u2010related outcomes: post hoc analyses from VERTIS CV","volume":"6","author":"Sridhar VS","year":"2023","journal-title":"J Am College Clin Pharm"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.08.016"},{"key":"e_1_2_10_30_1","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO Working Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14677"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2433"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1909"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916624"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915833"},{"key":"e_1_2_10_36_1","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad GC","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109080"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154918"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/13685538.2019.1678126"},{"key":"e_1_2_10_40_1","first-page":"145","article-title":"A novel marker for prediabetic conditions: uric acid\u2010to\u2010HDL cholesterol ratio","volume":"125","author":"Balci SB","year":"2024","journal-title":"Bratisl Lek Listy"},{"key":"e_1_2_10_41_1","first-page":"277","article-title":"Serum uric acid to hdl cholesterol ratio is associated with diabetic control in new onset type 2 diabetic population","volume":"62","author":"Kosekli MA","year":"2023","journal-title":"Acta Clin Croat"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2023.2214058"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.65.1.9"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20201005"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2022.2039007"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac320"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000699"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01657-9"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.09.022"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2265"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.05.022"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:03:56Z","timestamp":1761861836000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/dom.15895"],"URL":"https:\/\/doi.org\/10.1111\/dom.15895","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"2024-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}